These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9568608)

  • 21. [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
    Van Cutsem E; Peeters M
    Bull Cancer; 1998 Dec; Spec No():33-7. PubMed ID: 9932082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compassionate use programme of irinotecan in colorectal cancer patients in The Netherlands.
    ten Bokkel Huinink WW; van Groeningen CJ; Voest EE; Peters WG; Keizer HJ; de Witte JH
    Neth J Med; 2003 Jul; 61(7):249-56. PubMed ID: 14567522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of irinotecan in patients with advanced hepatocellular carcinoma.
    O'Reilly EM; Stuart KE; Sanz-Altamira PM; Schwartz GK; Steger CM; Raeburn L; Kemeny NE; Kelsen DP; Saltz LB
    Cancer; 2001 Jan; 91(1):101-5. PubMed ID: 11148565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA approves irinotecan as first-line therapy for colorectal cancer.
    Oncology (Williston Park); 2000 May; 14(5):652, 654. PubMed ID: 10853457
    [No Abstract]   [Full Text] [Related]  

  • 25. [Clinical activity spectrum of irinotecan].
    Cottu PH; Extra JM; Lerebours F; Espie M; Marty M
    Bull Cancer; 1998 Dec; Spec No():21-5. PubMed ID: 9932080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
    Mitry E; Ducreux M; Rougier P
    Bull Cancer; 1998 Dec; Spec No():38-42. PubMed ID: 9932083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CPT-11 (irinotecan) in the treatment of colorectal cancer: a new mechanism of action for additional activity.
    Bleiberg H
    Tumori; 1997; 83(1 Suppl):S85-6. PubMed ID: 9154078
    [No Abstract]   [Full Text] [Related]  

  • 29. CPT-11: clinical experience in phase I studies.
    Armand JP
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):27-33. PubMed ID: 8633250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vinorelbine tartrate (Navelbine): drug profile and nursing implications of a new vinca alkaloid.
    Brogden JM; Nevidjon B
    Oncol Nurs Forum; 1995 May; 22(4):635-46. PubMed ID: 7675666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colorectal cancer: dilemmas regarding patient selection and toxicity prediction.
    Nikolic-Tomasevic Z; Jelic S; Popov I; Radosavljevic D
    J Chemother; 2000 Jun; 12(3):244-51. PubMed ID: 10877521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CPT-11 (irinotecan) in the treatment of colorectal cancer.
    Armand JP; Ducreux M; Mahjoubi M; Abigerges D; Bugat R; Chabot G; Herait P; de Forni M; Rougier P
    Eur J Cancer; 1995; 31A(7-8):1283-7. PubMed ID: 7577037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer.
    Ikeguchi M; Arai Y; Maeta Y; Ashida K; Katano K; Wakatsuki T
    Surg Today; 2011 Sep; 41(9):1196-9. PubMed ID: 21874414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Irinotecan: toward clinical end points in drug development.
    Pazdur R
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):13-21. PubMed ID: 9726086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CPT-11: the European clinical development.
    Terret C; Couteau C; Armand JP
    J Infus Chemother; 1996; 6(3):152-7. PubMed ID: 9229329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective.
    Bleiberg H; Cvitkovic E
    Eur J Cancer; 1996; 32A Suppl 3():S18-23. PubMed ID: 8943661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Irinotecan for colorectal cancer: a small step forward.
    O'Connell MJ
    Lancet; 1998 Oct; 352(9138):1402. PubMed ID: 9807982
    [No Abstract]   [Full Text] [Related]  

  • 38. Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan.
    Kramar A; Gourgou-Bourgade S; Ychou M
    J Clin Oncol; 2005 Jan; 23(3):650; author reply 650-1. PubMed ID: 15659517
    [No Abstract]   [Full Text] [Related]  

  • 39. [Therapeutic approach for colorectal cancer with topoisomerase as a molecular target].
    Tsunoda T
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():472-5. PubMed ID: 14574938
    [No Abstract]   [Full Text] [Related]  

  • 40. Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.
    Swami U; Goel S; Mani S
    Curr Drug Targets; 2013 Jun; 14(7):777-97. PubMed ID: 23597015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.